Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361842 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00361842 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT00361842, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90 minutes every two weeks.
Interventions
- DRUG CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361842
The ClinicalTrials.gov registry entry for NCT00361842 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection is the first listed.
NCT00361842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00361842 about?
NCT00361842 is a clinical study titled "Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer". The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan. All patients will receive CPX-1 at a dose of 210 units/m2 over 90 minutes every two weeks.
What is the current status of trial NCT00361842?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00361842?
The interventions under investigation include: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection (DRUG).
Who is sponsoring clinical trial NCT00361842?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.